The US FDA has approved Dupixent (dupilumab) for treating children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who do not respond to standard antihistamine treatment. This marks the first biologic medicine approved for young children with this debilitating skin condition, which causes persistent itch and hives. The approval is based on clinical data showing Dupixent's effectiveness in reducing symptoms and improving disease control by targeting key inflammatory pathways. Dupixent is already approved for several other allergy-related conditions and this expansion highlights its growing role in treating type 2 inflammation-driven diseases in children.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
